Drug Development and Industrial Pharmacy 2014-11-01

Development and in vitro evaluation of a buccal drug delivery system based on preactivated thiolated pectin.

Sabine Hauptstein, Fabian Hintzen, Christiane Müller, Moritz Ohm, Andreas Bernkop-Schnürch

Index: Drug Dev. Ind. Pharm. 40(11) , 1530-7, (2014)

Full Text: HTML

Abstract

The aim of this study was to evaluate the potential of preactivated thiolated pectin (Pec-Cys-MNA) for buccal drug delivery. Therefore, a gel formulation containing this novel polymer and the model drug lidocaine was prepared and investigated in vitro in terms of rheology, mucoadhesion, swelling behavior and drug release in comparison to formulations based on pectin (Pec) and thiolated pectin (Pec-Cys). Both pectin derivatives showed gel formation without addition of any other excipient due to self-crosslinking thiol groups. Under same conditions, pectin did not show gel formation. Viscosity of Pec-Cys-based formulation increased 92-fold and viscosity of Pec-Cys-MNA-based formulations by 4958-fold compared to pectin-based formulation. Gels did not dissolve in aqueous environment during several hours and were able to take up water. Mucoadhesion of pectin on buccal tissue could be improved significantly, value of total work of adhesion increased in the following rank order: Pec-Cys-MNA > Pec-Cys > Pec. The retention time of a model drug incorporated in gel formulations on buccal mucosa under continuous rinsing with phosphate-buffered saline was prolonged, after 1.5 h 3-fold higher amount of a model drug was to be found on tissue after application of Pec-Cys-MNA-based formulation compared to pectin-based and 2-fold compared to Pec-Cys-based formulation. The Pec-Cys-MNA-based gel showed a more sustained release of lidocaine than Pec-Cys-based gel, whereas pectin solution revealed an immediate release. According to these results, the self-crosslinking pectin-derivative is a promising tool for buccal application.


Related Compounds

Related Articles:

Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.

2015-02-01

[Biomaterials 42 , 42-51, (2014)]

Altering in vivo macrophage responses with modified polymer properties.

2015-07-01

[Biomaterials 56 , 187-97, (2015)]

Species-dependent binding of new synthesized bicalutamide analogues to albumin by optical biosensor analysis.

2015-01-01

[J. Pharm. Biomed. Anal. 111 , 324-32, (2015)]

Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery.

2015-06-20

[Int. J. Pharm. 487 , 81-90, (2015)]

Development of poly (I:C) modified doxorubicin loaded magnetic dendrimer nanoparticles for targeted combination therapy.

2014-10-01

[Biomed. Pharmacother. 68(8) , 979-87, (2014)]

More Articles...